Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x100px
Document › Details

Epigenomics AG. (1/27/23). "Press Release: Resignation of Supervisory Board Chairman Heino von Prondzynski". Berlin.

Organisations Organisation Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY)
  Group Epigenomics (Group)
  Organisation 2 Roche Diagnostics (Group Division)
  Group Roche (Group)
Products Product Epi proColon® blood test
  Product 2 molecular diagnostics
Persons Person von Prondzynski, Heino (Roche Diagnostics + BB Medtech + several Boards)
  Person 2 Hamilton, Gregory (Greg) (Epigenomics 201607– CEO before AltheaDx + Enigma Diagnostics + Third Wave + Hologic)

The Chairman of the Supervisory Board of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “Company”), Heino von Prondzynski, today informed the Boards that he will resign from his mandate effective March 31, 2023, for health reasons and will leave the Supervisory Board at that time.

Greg Hamilton, CEO of Epigenomics AG, thanked Heino von Prondzynski on behalf of the entire Executive Board: “We deeply regret his departure as he is a proven expert and business leader in the field of molecular diagnostics. We would like to thank Heino von Prondzynski for his commitment, leadership and guidance to the Company and its employees. We wish him all the best health.”

Mr. von Prondzynski was a member of the Supervisory Board from May 2007 to March 2010, and has been Chairman of the Supervisory Board of Epigenomics AG since May 2012. Prior to that, he had an international career, among others as CEO of the Roche Diagnostics Division at F. Hoffmann-La Roche Ltd, Basel, Switzerland, and member of the corporate executive committee of Roche.

The Supervisory Board will appoint a successor from among its members at short notice.

About Epigenomics

Epigenomics AG is a molecular diagnostics company focused on blood testing for the early detection of cancer. Based on its proprietary biomarker technology for the detection of methylated DNA, Epigenomics develops and markets blood tests for various cancer indications with high unmet medical need. Epigenomics’ lead product is the blood test Epi proColon® for the early detection of colorectal cancer. Epi proColon is approved by the U.S. Food and Drug Administration (FDA) and is marketed in the United States and Europe as well as other selected countries. HCCBloodTest, a blood test for the detection of liver cancer, have received the CE Mark for marketing in Europe.

For further information please visit


Epigenomics AG, Geneststrasse 5, 10829 Berlin
Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, Email:

Investor Relations
IR.on AG, Frederic Hilke, Tel +49 221 9140 970, Email:

Note on forward-looking statements

This publication expressly or implicitly contains forward-looking statements concerning Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause Epigenomics AG’s actual results, financial condition and performance to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics makes this announcement as of the date of this release and does not intend to update any forward-looking statements contained herein as a result of new information or future events or otherwise.

Record changed: 2024-01-20


Picture Berlin Partner Top News Tacalyx Extends Seed Round to €14m 650x200px

More documents for Epigenomics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top